Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Share :
Published: 17 Oct 2023
Views: 86
Rating:
Save
Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Dr Shirish Gadgeel speaks to ecancer regarding the two-year follow-up of adagrasib monotherapy in patients with advanced or metastatic KRASG12C-mutated non-small cell lung cancer. The results were presented at the World Conference on Lung Cancer 2023.

The study showed a median overall survival of 14.1 months at 26.9 months follow-up. The 1-year OS rate was 52.8%, and the 2-year OS rate was 31.3%. 

He continues to discuss the median progression-free survival which as 6.9 months, while the 1-year PFS rate was 35.0% and the 2-year PFS rate was 13.9%. Additionally, the objective response rate was 43%, with the median duration of response being 12.4 months.

The findings of the study indicate that adagrasib offers durable clinical benefit with no new safety signals. 

Dr Gadgeel concludes by highlighting that these results are promising given the limited treatment options currently available for patients with advanced or metastatic KRASG12C-mutated non-small cell lung cancer.